Feed PBIGF
PB

Paradigm Biopharmaceuticals Limited

PBIGF · OTC

$0.18 -3.16% (-$0.01)
1M +84.00%
Market Cap $159.0M
P/E Ratio -
Div. Yield -
ROE 347.77%
Piotroski F-Score Weak
2/9
Valuation
0 /100
Expensive
P/B 45.89x
P/S 1,987.14x
P/FFO N/A
Growth
0 /100
Declining
Book val. growth 59.88%
FCF growth N/A
EPS growth N/A
Profitability
0 /100
Weak
Op. margin 76,248.10%
Gross margin 102.77%
FCF margin 54,507.20%
Quality
0 /100
Poor
ROA 184.36%
ROIC 484.07%
Asset turnover 0.00x
Debt
17 /100
High
Int. coverage -24.83x
Debt/Equity 2.16x
Current ratio 1.10x
Stability
19 /100
Unstable
Profitable years 0
Beta -0.02x
EPS volatility 121.06%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about PBIGF
Online

Sector

Healthcare

Industry

Biotechnology

CEO

Paul John Rennie

Employees

8

Headquarters

Melbourne

Upcoming events

24 FEB

Earnings

Upcoming earnings report

165d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.